Supernus Pharmaceuticals (NASDAQ:SUPN) Earns Buy Rating from Mizuho

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating reissued by analysts at Mizuho in a research note issued on Thursday, March 28th, AnalystRatings.com reports. They currently have a $63.00 target price on the specialty pharmaceutical company’s stock. Mizuho’s price objective suggests a potential upside of 74.66% from the stock’s previous close.

The analysts wrote, “We note placebo response in P304 appears higher than in prior trials. Effect sizes in the pediatric Phase III trial were 0.49 in the 400 mg arm and 0.50 in the adolescent trial P302, so this was the strongest efficacy finding in the 400 mg dose to date. The drug also demonstrated statistically significant improvements on both subscales of hyperactivity and inattention. The company still plans to submit its NDA filing in 2H:19 and has adequate data to support approval, in our view. We reiterate our Buy rating and $63 PT, which assumes sales of SPN-812 could approach $600M by 2026.””

SUPN has been the topic of a number of other research reports. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Cantor Fitzgerald set a $57.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, January 10th. ValuEngine cut shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. BidaskClub cut shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 22nd. Finally, B. Riley set a $65.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, March 4th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $55.75.

SUPN stock traded up $1.01 during mid-day trading on Thursday, reaching $36.07. 960,596 shares of the company traded hands, compared to its average volume of 586,309. The company has a market capitalization of $1.89 billion, a P/E ratio of 17.60 and a beta of 1.59. The company has a debt-to-equity ratio of 0.73, a quick ratio of 2.90 and a current ratio of 3.06. Supernus Pharmaceuticals has a fifty-two week low of $30.05 and a fifty-two week high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.21. Supernus Pharmaceuticals had a return on equity of 27.45% and a net margin of 27.14%. The firm had revenue of $113.50 million for the quarter, compared to the consensus estimate of $105.36 million. During the same quarter in the previous year, the business earned $0.26 EPS. The company’s revenue was up 31.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Supernus Pharmaceuticals will post 2.37 earnings per share for the current fiscal year.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 20,000 shares of the business’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $41.53, for a total transaction of $830,600.00. Following the sale, the chief financial officer now owns 67,896 shares of the company’s stock, valued at approximately $2,819,720.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.20% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SUPN. Victory Capital Management Inc. grew its position in shares of Supernus Pharmaceuticals by 74.0% during the 3rd quarter. Victory Capital Management Inc. now owns 7,240 shares of the specialty pharmaceutical company’s stock valued at $365,000 after purchasing an additional 3,080 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in Supernus Pharmaceuticals in the third quarter worth $364,000. Janney Montgomery Scott LLC grew its position in Supernus Pharmaceuticals by 28.1% in the third quarter. Janney Montgomery Scott LLC now owns 13,860 shares of the specialty pharmaceutical company’s stock worth $698,000 after acquiring an additional 3,039 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Supernus Pharmaceuticals by 13.8% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,465 shares of the specialty pharmaceutical company’s stock worth $628,000 after acquiring an additional 1,509 shares in the last quarter. Finally, BlackRock Inc. grew its position in Supernus Pharmaceuticals by 4.1% in the third quarter. BlackRock Inc. now owns 8,003,001 shares of the specialty pharmaceutical company’s stock worth $402,951,000 after acquiring an additional 312,332 shares in the last quarter. Hedge funds and other institutional investors own 99.18% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Read More: Green Investing

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.